Evidence map›Paper›PMID 41570088›Full record

ArticleBioinformatics (Oxford, England)2026

De novo protein-ligand design including protein flexibility and conformational adaptation.

Jakob Agamia, Martin Zacharias

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jakob AgamiaCenter of Functional Protein Assemblies and Physics Department, Technical University Munich, Bavaria 85748, Germany.
Martin ZachariasCenter of Functional Protein Assemblies and Physics Department, Technical University Munich, Bavaria 85748, Germany.ORCID 0000-0001-5163-2663

Funding

Deutsche Forschungsgemeinschaft DFG Za153/29-1Erlangen National High Performance Center b118bb
6 · The paper itself

Abstract

motivationThe rational design of chemical compounds that bind to a desired protein target molecule is a major goal of drug discovery. Most current molecular docking but also fragment-based buildup or machine learning-based generative drug design approaches employ a rigid protein target structure.

resultsBased on recent progress in predicting protein structures and complexes with chemical compounds, we have designed an approach, AI-MCLig, to optimize a chemical compound bound to a fully flexible and conformationally adaptable protein binding region. During a Monte Carlo (MC)-type simulation to randomly change a chemical compound, the target protein-compound complex is completely rebuilt at every MC step using the Chai-1 protein structure prediction program. Besides compound flexibility it allows the protein to adapt to the chemically changing compound. MC protocols based on atom-/bond-type changes or based on combining larger chemical fragments have been tested. Simulations on four test targets resulted in potential ligands that show very good binding scores comparable to experimentally known binders using several different scoring schemes. The MC-based compound design approach is complementary to existing approaches and could help for the rapid design of putative binders including induced fit of the protein target. AVAILABILITY AND IMPLEMENTATION: Datasets, examples, and source code are available on our public GitHub repository https://github.com/JakobAgamia/AI-MCLig and on Zenodo at https://doi.org/10.5281/zenodo.17800140.

Indexed as

Drug DesignProteinsBinding SitesLigandsMolecular Docking SimulationMonte Carlo MethodProtein BindingProtein ConformationLigandsProteins

Identifiers

PMID41570088
PMCPMC12944823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.